Jens Juul Holst

Jens Juul Holst

Professor


  1. Published

    Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

    Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

    Deacon, Carolyn F., Carr, R. D. & Holst, Jens Juul, 2008, In: Frontiers in Bioscience. 13, p. 1780-94 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Differential regional metabolism of glucagon in anesthetized pigs.

    Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

    Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

    Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

    Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-140 8 p.

    Research output: Contribution to journalReviewResearchpeer-review

ID: 4207